Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage.
BACKGROUND
Gene therapy of familial hypercholesterolemia (FH) requires successful transfer and lifelong expression of a functional low density lipoprotein receptor (LDLr) gene in the liver. Most of the vector systems currently employed for gene therapy use promoter elements which do not modulate transgene expression in a physiological manner.


METHODS
To study the in vivo effects of constitutive LDLr gene expression in the absence of interfering immunological reactions we established a new mouse model which combines homozygous LDLr deficiency and severe combined immune deficiency (SCID).


RESULTS
Adenovirus-mediated transfer and expression of the LDLr gene under the control of a commonly used virus-derived promoter (minimal CMV promoter) leads to prolonged reduction of serum cholesterol levels in LDLr-deficient SCID mice. During the first 10 days after gene therapy serum cholesterol drops to about 10% of pretherapeutic values. Serum cholesterol persists on this level for 2 weeks and then slowly starts to rise again. Four months after vector application serum levels have reached about 40% of pretherapeutic values. However, as early as 5 days after gene transfer, the histological analysis of liver sections revealed the formation of crystalline lipid/cholesterol deposits in the cytosol of hepatocytes. During the following 8 weeks the amount of crystals increased in size and density. The intracellular storage of lipid and cholesterol reduced cell viability and induced an accelerated loss of therapeutic DNA from mice livers as was shown in a comparative expression study employing a transgene with a different metabolic function (human alpha 1-antitrypsin).


CONCLUSIONS
The non-physiological constitutive overexpression of an LDL receptor gene induces an imbalance between the speed of LDL uptake and metabolism which leads to pathological accumulation of lipids and cholesterol in hepatocytes. To protect cells from negative effects of LDLr overexpression, future vector design should consider the use of physiologically controlled expression elements.
Cichon
Guenter
G
Department of Molecular Cell Biology, Humboldt-University Berlin at the Max Delbrueck Center for Molecular Medicine, Robert-Roessle-Str. 10, 13125 Berlin, Germany. gcichon@mdc-berlin.de
Willnow
Thomas
T
Herwig
Susanne
S
Uckert
Wolfgang
W
Löser
Peter
P
Schmidt
Hartmut H
HH
Benhidjeb
Tahar
T
Schlag
Peter M
PM
Schnieders
Frank
F
Niedzielska
Dagmara
D
Heeren
Joerg
J
D000818:Animals; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D015316:Genetic Therapy; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000628:therapy; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D011817:Rabbits; D011973:Receptors, LDL / Q000235:genetics* / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000235:genetics / Q000378:metabolism
D011973:Receptors, LDL; C043392:SERPINA1 protein, human; D000515:alpha 1-Antitrypsin; D002784:Cholesterol